This story was produced with the USC Center For Health Journalism's National Fellowship and Kaiser Health News.
While the drug’s $94,500 cost puts it out of reach of the uninsured patients who use the Florida clinic, the drug’s maker provides it for free to qualified, low-income patients.
California says the expense of new hep C drugs has nothing to do with who is prescribed them. But the question lingers: With some 200,000 people living with hep C in Medi-Cal, how much of a factor is cost in determining which patients receive treatment?
Last year marked a turning point for people living with chronic hep C and public radio reporter Kristin Gourlay led the way in documenting the bittersweet promise of new treatments. In this post, she shares how she reported the series and the resources she found invaluable.
What’s the price of a human life? In this part of our series “At the Crossroads: The Rise of Hepatitis C and The Fight To Stop It,” we'll tell you what value health economists put on human life.
